LINC02893: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC02893

NCBI ID: G440173

LINC02893

Other Name(s): long intergenic non-protein coding RNA 2893 | Long intergenic non-protein coding RNA 2893

LINC02893: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Introduction

LINC02893 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various studies as a potential drug target or biomarker. It is located at position -229.7 on chromosome 6 and has a unique open reading frame (ORF) of 21 amino acids. LINC02893 is a non-coding RNA that is expressed in various tissues and organs, including brain, heart, and liver. It is highly expressed in the brain, and its expression level is significantly higher than that of its protein counterpart. LINC02893 is also known as LINC02893-AS1 and has been shown to play a role in various cellular processes, including cell adhesion, migration, and survival.

Drug Target Potential

LINC02893 has been identified as a potential drug target due to its unique ORF and its expressed levels in the brain. It is highly expressed in the brain and has been shown to play a role in various brain-related processes, including the development and progression of neurodegenerative diseases. LINC02893 has also been shown to interact with various protein substrates, including the protein known as PDGF-尾. This interaction suggests that LINC02893 may be a useful target for drugs that are currently being developed to treat neurodegenerative diseases.

Biomarker Potential

LINC02893 has also been identified as a potential biomarker for various diseases, including neurodegenerative diseases. Its expression level is significantly higher in the brain than in other tissues, which suggests that it may be a useful biomarker for these diseases. LINC02893 has also been shown to play a role in the development and progression of various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. This suggests that it may be a useful biomarker for these diseases and can be used to monitor the effectiveness of currently being developed treatments.

Expression and Function

LINC02893 is a non-coding RNA that is expressed in various tissues and organs, including the brain. It is highly expressed in the brain, with the highest expression levels found in the hippocampus. LINC02893 is also shown to be expressed in other tissues, including the heart and the liver. It is a small RNA molecule that has a length of 21 amino acids.

LINC02893 has been shown to play a role in various cellular processes, including cell adhesion, migration, and survival. It is a positive regulator of the transcription factor SLUG, which is involved in the development and progression of cancer. LINC02893 is also shown to play a role in the regulation of the microRNA (miRNA) pathway, which is involved in the regulation of various cellular processes.

LINC02893 has also been shown to interact with various protein substrates, including the protein known as PDGF-尾. This interaction suggests that LINC02893 may be a useful target for drugs that are currently being developed to treat neurodegenerative diseases.

Conclusion

LINC02893 is a long intergenic non-protein-coding RNA that has been identified as a potential drug target and biomarker. Its unique ORF and high expression levels in the brain make it a promising target for drugs that are currently being developed to treat neurodegenerative diseases. Further research is needed to fully understand the role of LINC02893 in various cellular processes and its potential as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2893

The "LINC02893 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02893 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets